CRDL
Cardiol Therapeutics·NASDAQ
--
--(--)
--
--(--)
CRDL fundamentals
During Q3 2025, Cardiol Therapeutics (CRDL) reported revenue of --, a YoY change of 0.00%. Net income was -7.15M, a YoY change of 24.05%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | TTM |
|---|
Start Date | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | -- |
End Date | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | 63.50K -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Sales and Services Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | 63.50K -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gross Profit | -- -- | -- -- | -- -- | -- -- | -- -- | 63.50K -- | -- -- | -61.64K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 2.18M -- | 2.63M -- | 3.31M -- | 7.54M -- | 7.14M +227.88% | 5.24M +99.12% | 8.02M +142.25% | 10.25M +35.91% | 7.84M +9.78% | 7.17M +36.84% | 9.61M +19.87% | 6.72M -34.43% | 5.76M -26.59% | 4.77M -33.47% | 5.66M -41.16% | 6.08M -9.52% | 6.21M +7.83% | 5.66M +18.54% | 10.47M +85.03% | 6.94M +14.07% | 5.86M -5.57% | 5.64M -0.38% | 7.31M -30.16% | 25.74M -- |
Selling, General and Administrative Expenses | 1.41M -- | 1.20M -- | 1.87M -- | 1.86M -- | 5.01M +254.66% | 3.57M +196.98% | 5.97M +219.12% | 7.49M +301.72% | 4.76M -5.05% | 3.75M +4.96% | 5.91M -1.04% | 2.57M -65.69% | 2.70M -43.17% | 2.14M -42.84% | 3.75M -36.53% | 3.02M +17.57% | 3.75M +38.77% | 3.68M +71.61% | 7.69M +104.92% | 4.00M +32.42% | 3.25M -13.45% | 3.63M -1.27% | 3.87M -49.64% | 14.75M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | 7.91M -- | -- -- | -- -- | -- -- | 21.82M +175.79% | -- -- | -- -- | -- -- | 16.53M -24.21% | -- -- | -- -- | 3.75M -- | 3.02M -81.73% | 3.75M -- | 3.68M -- | 7.69M +104.92% | 4.00M +32.42% | 3.25M -13.45% | 3.63M -1.27% | 3.87M -49.64% | 14.75M -- |
Research and Development Expenses | 413.69K -- | 600.90K -- | 1.44M -- | 5.68M -- | 2.13M +415.11% | 1.67M +177.95% | 2.05M +42.19% | 2.76M -51.37% | 3.08M +44.65% | 3.42M +105.02% | 3.70M +80.94% | 4.15M +50.36% | 3.05M -0.99% | 2.63M -23.21% | 1.90M -48.56% | 3.06M -26.28% | 2.45M -19.59% | 1.98M -24.70% | 2.78M +45.82% | 2.94M -4.04% | 2.61M +6.48% | 2.01M +1.29% | 3.44M +23.81% | 10.99M -- |
Other Operating Expenses | 351.62K -- | 828.98K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | -2.18M -- | -2.63M -- | -3.31M -- | -7.54M -- | -7.14M -227.88% | -5.18M -96.71% | -8.02M -142.25% | -10.25M -35.91% | -7.84M -9.78% | -7.17M -38.52% | -9.61M -19.87% | -6.72M +34.43% | -5.76M +26.59% | -4.77M +33.47% | -5.66M +41.16% | -6.08M +9.52% | -6.21M -7.83% | -5.66M -18.54% | -10.47M -85.03% | -6.94M -14.07% | -5.86M +5.57% | -5.64M +0.38% | -7.31M +30.16% | -25.74M -- |
Non-Operating Income (Loss) | 90.86K -- | -29.77K -- | 7.16K -- | -37.49K -- | 55.97K -38.40% | -110.96K -272.75% | 200.12K +2694.82% | 5.35M +14379.90% | 668.47K +1094.30% | 2.13M +2020.47% | 3.82M +1806.94% | 1.17M -78.19% | 515.19K -22.93% | -874.47K -141.04% | 1.27M -66.59% | 296.78K -74.58% | -571.75K -210.98% | 840.74K +196.14% | 1.05M -18.04% | 1.26M +323.79% | 98.34K +117.20% | -497.95K -159.23% | 154.96K -85.17% | 1.01M -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 3.85M -- | -- -- | -- -- | -- -- | 4.61M +19.87% | -- -- | -- -- | 290.27K -- | 433.01K -90.61% | -1.34M -- | 505.00K -- | -- -- | 165.40K -61.80% | 0 +100.00% | 0 -100.00% | -- -- | -- -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | -- -- | -27.02K -- | -- -- | -- -- | -- -- | 1.48M +5580.97% | -- -- | -- -- | -- -- | 2.04M +37.83% | -- -- | -- -- | 493.20K -- | -475.80K -123.31% | 464.50K -- | 111.09K -- | -105.12K -121.31% | 1.04M +319.03% | -74.32K -116.00% | -630.60K -667.64% | 67.18K +163.91% | 404.41K -- |
Other Non-Operating Income (Loss) | 76.85K -- | -39.98K -- | -10.37K -- | -25.79K -- | 42.59K -44.58% | -131.50K -228.91% | 171.77K +1756.08% | 3.22K +112.49% | 610.54K +1333.57% | 1.98M +1607.43% | 3.53M +1956.87% | -5.92M -183753.48% | 111.55K -81.73% | -1.27M -164.27% | 110.63K -96.87% | 0 +100.00% | 20.84K -81.31% | 0 +100.00% | 1.00M +804.57% | -162.87K -- | 0 -100.00% | 0 -- | 0 -100.00% | -162.87K -- |
Net Interest Expense | -14.01K -- | -10.21K -- | -17.53K -- | -15.32K -- | -13.38K +4.48% | -20.54K -101.13% | -28.35K -61.71% | -21.73K -41.89% | -57.93K -332.87% | -148.66K -623.68% | -283.11K -898.58% | -432.05K -1888.07% | -403.64K -596.75% | -399.56K -168.78% | -380.89K -34.54% | -339.57K +21.40% | -278.65K +30.97% | -224.65K +43.78% | -149.41K +60.77% | -213.04K +37.26% | -172.66K +38.04% | -132.65K +40.95% | -87.78K +41.25% | -606.13K -- |
Interest Income | 14.01K -- | 10.21K -- | 17.53K -- | 15.32K -- | 13.38K -4.48% | 20.54K +101.13% | 28.35K +61.71% | 21.73K +41.89% | 57.93K +332.87% | 148.66K +623.68% | 283.11K +898.58% | 432.05K +1888.07% | 403.64K +596.75% | 399.56K +168.78% | 380.89K +34.54% | 339.57K -21.40% | 278.65K -30.97% | 224.65K -43.78% | 149.41K -60.77% | 213.04K -37.26% | 172.66K -38.04% | 132.65K -40.95% | 87.78K -41.25% | 606.13K -- |
Pretax Income From Continuing Operations | -2.09M -- | -2.66M -- | -3.30M -- | -7.58M -- | -7.09M -239.47% | -5.29M -98.67% | -7.82M -136.71% | -4.90M +35.39% | -7.17M -1.21% | -5.04M +4.68% | -5.80M +25.87% | -5.55M -13.40% | -5.24M +26.93% | -5.65M -12.00% | -4.38M +24.42% | -5.78M -4.16% | -6.78M -29.34% | -4.82M +14.70% | -9.42M -115.02% | -5.68M +1.82% | -5.76M +14.98% | -6.13M -27.35% | -7.15M +24.05% | -24.73M -- |
Income Tax Expense | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -2.09M -- | -2.66M -- | -3.30M -- | -7.58M -- | -7.09M -239.47% | -5.29M -98.67% | -7.82M -136.71% | -4.90M +35.39% | -7.17M -1.21% | -5.04M +4.68% | -5.80M +25.87% | -5.55M -13.40% | -5.24M +26.93% | -5.65M -12.00% | -4.38M +24.42% | -5.78M -4.16% | -6.78M -29.34% | -4.82M +14.70% | -9.42M -115.02% | -5.68M +1.82% | -5.76M +14.98% | -6.13M -27.35% | -7.15M +24.05% | -24.73M -- |
Net Income Attributable to Owners of the Company | -2.09M -- | -2.66M -- | -3.30M -- | -7.58M -- | -7.09M -239.47% | -5.29M -98.67% | -7.82M -136.71% | -4.90M +35.39% | -7.17M -1.21% | -5.04M +4.68% | -5.80M +25.87% | -5.55M -13.40% | -5.24M +26.93% | -5.65M -12.00% | -4.38M +24.42% | -5.78M -4.16% | -6.78M -29.34% | -4.82M +14.70% | -9.42M -115.02% | -5.68M +1.82% | -5.76M +14.98% | -6.13M -27.35% | -7.15M +24.05% | -24.73M -- |
Net Income Attributable to Common Stockholders | -2.09M -- | -2.66M -- | -3.30M -- | -7.58M -- | -7.09M -239.47% | -5.29M -98.67% | -7.82M -136.71% | -4.90M +35.39% | -7.17M -1.21% | -5.04M +4.68% | -5.80M +25.87% | -5.55M -13.40% | -5.24M +26.93% | -5.65M -12.00% | -4.38M +24.42% | -5.78M -4.16% | -6.78M -29.34% | -4.82M +14.70% | -9.42M -115.02% | -5.68M +1.82% | -5.76M +14.98% | -6.13M -27.35% | -7.15M +24.05% | -24.73M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -2.09M -- | -2.66M -- | -3.30M -- | -7.58M -- | -7.09M -239.47% | -5.29M -98.67% | -7.82M -136.71% | -4.90M +35.39% | -7.17M -1.21% | -5.04M +4.68% | -5.80M +25.87% | -5.55M -13.40% | -5.24M +26.93% | -5.65M -12.00% | -4.38M +24.42% | -5.78M -4.16% | -6.78M -29.34% | -4.82M +14.70% | -9.42M -115.02% | -5.68M +1.82% | -5.76M +14.98% | -6.13M -27.35% | -7.15M +24.05% | -24.73M -- |
Total Comprehensive Income Attributable to Owners of the Company | -2.09M -- | -2.66M -- | -3.30M -- | -7.58M -- | -7.09M -239.47% | -5.29M -98.67% | -7.82M -136.71% | -4.90M +35.39% | -7.17M -1.21% | -5.04M +4.68% | -5.80M +25.87% | -5.55M -13.40% | -5.24M +26.93% | -5.65M -12.00% | -4.38M +24.42% | -5.78M -4.16% | -6.78M -29.34% | -4.82M +14.70% | -- -- | -25.47M -340.30% | -5.76M +14.98% | -6.13M -27.35% | -- -- | -- -- |
Basic EPS | -0.08 -- | -0.1 -- | -0.1 -- | -- -- | -0.21 -162.50% | -0.13 -30.00% | -0.18 -80.00% | -0.08 -- | -0.11 +47.62% | -0.08 +38.46% | -0.09 +50.00% | -0.09 -12.50% | -0.08 +27.27% | -0.09 -12.50% | -0.07 +22.22% | -0.09 -- | -0.1 -25.00% | -0.07 +22.22% | -0.13 -85.71% | -0.07 +22.22% | -0.07 +30.00% | -0.07 -- | -0.09 +30.77% | -0.3 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.07 -- | -- -- | -0.1 -- | -0.07 -- | -0.13 -85.71% | -- -- | -0.07 +30.00% | -0.07 -- | -0.09 +30.77% | -- -- |
Diluted EPS | -0.08 -- | -0.1 -- | -0.1 -- | -- -- | -0.21 -162.50% | -0.13 -30.00% | -0.18 -80.00% | -- -- | -0.11 +47.62% | -0.08 +38.46% | -0.09 +50.00% | -- -- | -0.08 +27.27% | -0.09 -12.50% | -0.07 +22.22% | -- -- | -0.1 -25.00% | -0.07 +22.22% | -0.13 -85.71% | -- -- | -0.07 +30.00% | -0.07 -- | -0.09 +30.77% | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.07 -- | -- -- | -0.1 -- | -0.07 -- | -0.13 -85.71% | -- -- | -0.07 +30.00% | -0.07 -- | -0.09 +30.77% | -- -- |
You can ask Aime
What does Cardiol Therapeutics do and what are its main business segments?What guidance did Cardiol Therapeutics's management provide for the next earnings period?What is the revenue and EPS growth rate for Cardiol Therapeutics year over year?What is Cardiol Therapeutics's gross profit margin?Did Cardiol Therapeutics beat or miss consensus estimates last quarter?What is the market's earnings forecast for Cardiol Therapeutics next quarter?What were the key takeaways from Cardiol Therapeutics’s earnings call?What factors drove the changes in Cardiol Therapeutics's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
